HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Communication, education can break taboo of sexual dysfunction in patients with cancer

Editorial

When loss becomes personal: Reflections on one of our own

Derek Raghavan, MD, PhD

FDA News

FDA grants orphan drug designation to AG-120 for AML

FDA grants orphan drug designation to ImMucin for multiple myeloma

FDA grants orphan drug designation for APTO-253 for AML

FDA grants priority review to MM-398 for metastatic pancreatic cancer

In the Journals

Promoter mutations redefine molecular subgroups of gliomas

PTEN, KLLN mutations provide insight into Cowden disease-related endometrial cancer

Mohs micrographic surgery may effectively treat rare hidradenocarcinoma

Intraperitoneal chemotherapy prolongs OS in advanced ovarian cancer

Genomic data may better classify lower-grade glioma than histology

Pharmacist-managed medication refill clinics ease physician workload

ASCO creates framework to measure value of cancer treatment

Sunitinib benefits some patients with non-clear cell renal cell carcinoma

Sociodemographic factors affect thyroid cancer survival rates in young adults

Institution Notes

Immunology chairman receives award for cancer research

University selects chair for newly created otolaryngology department

Nurse researcher named journal editor

Society of breast surgeons installs new president

ISTH presents Grant Medal to pediatrics professor

Meeting News Coverage

Pediatric soft tissue sarcoma survivors at risk for chronic medical conditions

Palbociclib plus hormone therapy slows progression of HR-positive breast cancer

Pembrolizumab shows promise for advanced bladder cancer

Whole-lung radiation may not be necessary in favorable histology Wilms' tumor responders

Statin, metformin combination reduces prostate cancer mortality, particularly among obese men

Researchers find Inlyta/TACE safe, well-tolerated in Chinese patients with HCC

POPLAR: Inhibition of the PD-L1/PD-1 pathway may improve survival in NSCLC

Protocol safely guides perioperative management of dabigatran

ECX chemotherapy shows some benefit without OS improvement in advanced esophageal cancer

Early reduction in CTCs leads to survival benefit in prostate cancer

KEYNOTE-001: Findings support pembrolizumab in melanoma

Investigational compound targets FGFR pathway

Activating KIR genes influence MDS risk, outcome

30-month complete response serves as PFS surrogate for follicular lymphoma

DCIS survival benefit from surgery varies by nuclear grade

Carfilzomib significantly improves PFS in relapsed multiple myeloma

Lower dose of polatuzumab vedotin safe, effective for follicular lymphoma

Novel recombinant Factor VIII appears safe, effective in severe hemophilia A

Obinutuzumab, bendamustine significantly extend PFS in relapsed non-Hodgkin's lymphoma

Pacritinib improves symptom control, reduces spleen volume in patients with myelofibrosis

Neratinib prolongs invasive DFS in HER-2–positive early-stage breast cancer

Mutational profiles of HPV-positive, HPV-negative tumors differ

Mismatch repair deficiency predicts response to pembrolizumab in several cancer types

Nedaplatin plus docetaxel ‘new standard of treatment’ for advanced squamous lung carcinoma

Supplement

Perspectives from ASCO 2015: A HemOnc Today Special Report

morganatic-roan